Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 25 for “"Infliximab"”.
-
Monitorización de niveles de Infliximab y anticuerpos Anti-Infliximab en pacientes con enfermedad inflamatoria intestinal en práctica clínica
Introducción Infliximab (IFX) es un fármaco anti-TNF que consigue una buena tasa de respuesta y remisión en muchos pacientes con enfermedad inflamatoria intestinal (EII). No obstante, entre el 30-40% de los pacientes tratados con IFX pierden la respuesta durante el periodo de mantenimiento del …
-
Análisis costo versus efectividad del Etanercept, Infliximab y Adalimumab, en pacientes con artritis reumatoide refractaria
… de Salud (EPS) en Colombia: el Etanercept, Infliximab y Adalimumab. Dicho análisis se realizará de manera cuantitativa, para poder determinar cuál de ellos es la primera opción más costo-efectiva.
-
Variazione dei markers di attivata coagulazione indotta dalla terapia infusionale con Infliximab in pazienti affetti da malattie infiammatorie croniche intestinali
… samples obtained before and 1 hour after 24 infliximab infusions (5 mg/kg) in 9 IBD patients (5 men and 4 women; mean age: 47.6+17.6 years; 4 Crohn's disease, 4 Ulcerative Colitis,1 Indeterminate Colitis). F1+2 and D-dymer levels were measured in each sample using ELISA methods.The data were …
-
Eficacia y seguridad del biosimilar ABP 501 (Adalimumab) comparado con biosimilar CT-P13 (Infliximab) en pacientes adultos con artritis reumatoide. Revisión sistemática
… ABP 501 (Adalimumab), Biosimilar CT-P13 (Infliximab). Metodología: Se realizó una revisión sistemática de la literatura que incluyó estudios de intervención, evaluando las respuestas clínicas de acuerdo a las escalas ACR20,ACR50, ACR 70 , DAS 28 PCR, y de seguridad evaluados por formación …
-
Biologinės terapijos taikymas pacientams, sergantiems autoimuniniais artritais /
… significant differences in efficacy of various infliximab dosages were not detected. Mild and moderate adverse events were most common during treatment with BD. Low agreement of tuberculin skin test and interferon-γ release assay for diagnosing latent tuberculosis (TB) before initiation of BD …
-
Biologic therapy in patients with autoimmune arthritis /
… significant differences in efficacy of various infliximab dosages were not detected. Mild and moderate adverse events were most common during treatment with BD. Low agreement of tuberculin skin test and interferon-γ release assay for diagnosing latent tuberculosis (TB) before initiation of BD …
-
Valoración de la eficacia de Infliximab biosimilar (CT-P13, remsima®) frente al Infliiximab original (Remicade®) en pacientes con enfermedad inflamatoria intestinal.
… Europea (EMA) aprobó el primer biosimilar del Infliximab (CT-P13) con las mismas indicaciones del medicamento de referencia, basados en los análisis obtenidos de dos estudios realizados en pacientes con enfermedades reumatológicas. Esta extrapolación de resultados, así como la sustitución del …
-
Treatment of arthritis with tumour necrosis factor antagonists. Clinical, immunological and biochemical aspects
… of infusion reactions during treatment with infliximab. All the patients who participated in the studies were monitored according to a standardised clinical protocol of the South Swedish Arthritis Treatment Group (SSATG) developed at the Department of Rheumatology in Lund. We found that such …
-
Optimisation of analytical methods for monitoring monoclonal antibody therapy in Inflammatory Bowel Disease
… treated with the monoclonal antibody therapies Infliximab and adalimumab. However, low drug levels and immunogenicity (development of anti-drug antibodies) are associated with treatment failure. Therapeutic drug monitoring, using drug and anti-drug antibody measurements improves treatment …
-
Optimización del rango terapéutico de niveles de fármaco y anti-fármaco de terapia biológica anti-tnf-alfa en artritis reumatoide
… con fármacos biológicos anti-TNF-alfa (infliximab, adalimumab y etanercept) ha mejorado el pronóstico, pero su eficacia puede verse afectada por la formación de anticuerpos antifármaco y estar condicionada por la variabilidad en niveles de fármaco. Este estudio se centra en la …
-
Therapie der Spondylitis ankylosans mit dem monoklonalen chimären anti-TNF-Antikörper Infliximab (Remicade®):Klinische Wirksamkeit und Einfluss auf die HLA-Oberflächenexpression auf Lymphozyten mit besonderer Berücksichtigung von HLA-B27
… wurde an 10 Patienten während einer 60wöchigen Infliximabtherapie eine Evaluation von Therapiewirksamkeit und -sicherheit, sowie eine durchflusszytometrische Analyse der HLA-Oberflächenexpression auf Lymphozyten vorgenommen. Von 8 Patienten wurde die Therapie ohne ernste Nebenwirkungen gut …
-
Adesão ao tratamento com infliximabe em pacientes com doenças inflamatórias imunomediadas atendidos em um centro de infusão de um hospital universitário em Salvador – BA
Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases; however, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients …
-
HIDRADENITIS SUPPURATIVA WITH 20 OR MORE DRAINING TUNNELS: A NATION-WIDE RETROSPECTIVE STUDY.
… treatment options, including guselkumab (4), infliximab (3), risankizumab (1) and ustekinumab (1). At univariate regression analysis, gluteal involvement was a negative predictor of IHS4-55 achievement with adalimumab at 12-16, 52 and 104 weeks. Conclusions: The results of this study do not …
-
Measure for measure. Outcome assessment of arthritis treatment in clinical practice
… treatment with adalimumab, etanercept or infliximab, date of treatment start and stop, core set variables and EQ-5D were recorded, and various activity indices, responses and EQ-5D utility were calculated. Descriptive statistics and completer analysis were used. The NNQ was calculated as …
-
Monoclonal Antibody Expression and Novel Purification in Nicotiana benthamiana
… (rituximab), Humira (adalimumab) and Remicade (infliximab), which are cornerstones in this type of sector. With the cost of development to market approval rising astronomically for a new drug, new ways to produce and process these molecules becomes a paramount objective to ultimately help both …
-
Outcomes of Immune Checkpoint Inhibitor-Mediated Colitis: Multicenter Cohort Study
… were grade 3 IMC (P=0.049) and reception of infliximab or vedolizumab (P=0.044). Sixteen patients (2.4%) had colonic perforation, 7 of them underwent surgical resection of a part of the colon. No IMC-related death was recorded. In conclusion, IMC can lead to colonic perforation requiring …
-
Markers and outcome measures in chronic immune mediated artrhritis: from association studies to prediction models.
… RA are evaluated. 511 RA patients treated with infliximab are investigated. After a loading regimen at week 0, 2, 6 and 14, the treating rheumatologist could decide to give a dose increase at week 22. This decision to give a dose increase can be considered as a measure of insufficient response …
-
Approvals, Utilization, and Cost of Biologics for the Treatment of Rheumatoid Arthritis
… following FDA authorization of biosimilars for infliximab, rituximab, and adalimumab. The annual cost at market entry was significantly positively correlated with FDA approval dates and TNFi classification.</p> <p><strong>Conclusions: </strong>The multifaceted nature of biologic therapy in RA …
-
The Genetics of IBD: From Susceptibility to Drug Response and Patient Outcome
… develop immunogenicity within the first year of infliximab monotherapy treatment (a common anti-TNF treatment regime). In the second research chapter of my thesis, I describe a genome-wide association study of thiopurine-induced liver damage (TILI). Ultimately, the study was underpowered to …
Page 1 of 2